Acquisitions (Recothrom) (Details) (USD $)	3 Months Ended			1 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Feb. 28, 2013 Bristol-Myers Squibb [Member] period	Feb. 28, 2013 Product License [Member] Bristol-Myers Squibb [Member]
Business Acquisition [Line Items]
Collaboration term				2 years
Option fee				$ 105,000,000
Assets acquired and liabilities assumed				10,000,000
Number of periods preceding closing of purchase				2
Period preceding closing of purchase				12 months
Period of collaboration term				24 months
Assets Acquired:
Intangible asset					32,800,000
Goodwill	144,262,000		14,671,000	25,100,000
Option				57,100,000
Total Assets				115,000,000
Total cash price paid upon acquisition				115,000,000
Pro Forma Information:
Net revenue	155,753,000	143,222,000
Net (loss) income	$ (12,260,000)	$ 1,122,000
Basic and diluted (loss) income per common share (USD per share)	$ (0.23)	$ 0.02